Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Trine Lauritzen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vestre Viken Trust, Drammen Hospital, Drammen, Norway. Hauptthemen laut MEDLINE: Atorvastatin, Mevalonic Acid, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Coronary Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vestre Viken Hospital Trust, South-Eastern Norway Regional Health Authority, Helse Sør-Øst RHF.
Abstract (Originalsprache)
Statin‐associated muscle symptoms are frequently reported and often lead to discontinuation of statin therapy with an increased risk of cardiovascular events. In vitro studies suggest that statin‐mediated inhibition of the mevalonate pathway leads to muscle cell toxicity. We aimed to determine the relationship between mevalonate, LDL‐cholesterol, and atorvastatin metabolites in patients with coronary heart disease and self‐perceived muscle side effects. Furthermore, we assessed the correlation between mevalonate in blood and muscle and the relationship to statin intolerance due to muscle symptoms. We used blood plasma from a randomized crossover trial ( n = 70) and muscle biopsies and plasma from a subgroup in a subsequent open intervention study ( n = 26). Both studies tested atorvastatin 40 mg/day. Seven patients did not tolerate ≥3 statins throughout the follow‐up and were classified as statin‐intolerant. Mevalonate in blood plasma decreased during atorvastatin treatment (median difference −38%, range −77% to 43%, p < 0.001), whereas mevalonate in muscle tissue was not lowered (0.05%, range −47% to 145%). Mevalonate correlated poorly with LDL‐cholesterol and atorvastatin metabolites (Spearman's rho −0.28 to 0.10). The statin‐intolerant patients had a smaller reduction in circulating mevalonate compared with the tolerant patients; median difference −8.1 (−22 to 3.5) nmol/L versus −25 (−93 to 12) nmol/L, p = 0.028. A similar observation was made for LDL‐cholesterol. Cutoffs based on these biomarkers classified >50% correctly as tolerant. Inhibition of the mevalonate pathway does not appear to be the mechanism underlying statin intolerance in the present study. Further studies of mevalonate as a biomarker for statin tolerance are needed to clarify the potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Vestre Viken Trust, Drammen Hospital, Drammen, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Laboratory Medicine, Vestre Viken Trust, Drammen Hospital, Drammen, Norway.
- Department of Behavioural Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
- Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
- Department of Pharmacy, University of Oslo, Oslo, Norway.
ORCID-Profile: Trine Lauritzen, John Munkhaugen, Stein Bergan, Elise Sverre, Sofia Lindahl, Einar Husebye, Nils Tore Vethe
Förderung
- Vestre Viken Hospital Trust
- South-Eastern Norway Regional Health Authority
- Helse Sør-Øst RHF
Zitieren
APA
Lauritzen, T., Munkhaugen, J., Bergan, S., Sverre, E., Peersen, K., Lindahl, S., Husebye, E., & Vethe, N. T. (2024). Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease. Clinical and Translational Science. https://doi.org/10.1111/cts.70025
Vancouver
Lauritzen T, Munkhaugen J, Bergan S, Sverre E, Peersen K, Lindahl S, et al. Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease. Clinical and Translational Science. 2024. doi:10.1111/cts.70025
BibTeX
@article{Lauritzen2024,
author = {Lauritzen, Trine and Munkhaugen, John and Bergan, Stein and Sverre, Elise and Peersen, Kari and Lindahl, Sofia and Husebye, Einar and Vethe, Nils Tore},
title = {Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70025}
}
EUVIMED